MHRA Details Regulatory Arrangements for No-Deal Brexit

Drug Industry Daily
A A
The UK’s Medicines and Healthcare products Regulatory Agency released new details of how it plans to continue drug regulatory operations if there is no Brexit deal by March 29 — including new fees to cover its added regulatory burden.

To View This Article:

Login

Subscribe To Drug Industry Daily